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Introduction
Dementia is a common, progressive disorder impairing brain function and affecting sufferers and 
caregivers’ wellbeing. Numbers of dementia patients will increase as the population ages. Rosmarinic 
acid is a natural compound with choline esterase inhibitory potency found in members of the botanical 
family lamiaceae, including sage, rosemary, and lemon balm, suggesting potential efficacy in 
dementia intervention. This study aimed to evaluate effectiveness of these herbs based on a review of 
randomised controlled trials.
Methods
Database searches were conducted separately for each herb using PubMed, the Cochrane Library, and 
ScienceDirect for clinical evidence for sage (Salvia officinalis L. or S. lavandulaefolia Vahl), 
rosemary (Rosmarinus officinalis L.), and lemon balm (Melissa officinalis L.), administered 
individually.
Results
Database searching identified 235, 112, and 177 articles for sage, rosemary, and lemon balm, 
respectively. From these, eight for sage, five for rosemary and eight for lemon balm met inclusion 
criteria. Trials were analysed based on the study designs and summarized as narrative synthesis as 
data were heterogeneous in terms of the target populations, herbal preparations and administration 
methods. 
Studies suggested sage spp. could improve cognitive performance and alertness. Rosemary 
could improve cognitive performance and alertness. Among eight articles identified on lemon balm, 
seven studies found it effective in improving mood or cognition. One study found no effect. 
Conclusions
Some clinical evidence supports the benefit of these herbs in dementia intervention. However, 
methodological heterogeneity and variable trial quality made information synthesis difficult. Further 
research is required to determine dosage and intervention periods.

1. Introduction
1.1. Dementia
Dementia is defined as a long lasting loss of mental ability. Its  prevalence was estimated to be 47.5 
million worldwide in 2015 (WHO, 2015), and it is likely to rise to 66 million by 2030 and 115 million 
by 2050 (Wortmann, 2012). Alzheimer’s disease (AD) and vascular dementia (VD) are the most 
common forms of dementia, accounting for 60-70% and 20% of total, respectively (WHO, 2015). 
Dementia not only affects the quality of life (QoL) of patients but also has a significant influence on 
the wellbeing of families and caregivers. Global societal and economic impact, including direct 
medical costs, direct social costs, and the costs of informal care, and is estimated to be 1.0% of the 
worldwide GDP (WHO, 2015).
Early signs of dementia include having difficulty remembering and solving simple 
mathematical problems, repeating the same questions, getting lost, and losing things. Later signs 
include trouble performing simple daily activities, confusion and disorientation, personality changes, 
hallucinations, and problems with language and speech (Alzheimer's society, 2014a, b; National 
Institute of Aging US, 2011). Stress and anxiety caused by cognitive impairment, as well as agitation, 
are also the common features that are highly distressing to patients and their caregivers (Dickson et 
al., 2012). Although amyloid-β (Aβ) deposition is the well-known hallmark of neuropathology of AD, 
the aetiological link is not yet resolved as only a small percentage of patients carry genetic mutations 
in the related genes (De Strooper and Karran, 2016; Lee et al., 2010). Meanwhile, oxidative stress has 
been found to be an important culprit in the development of AD (De Strooper and Karran, 2016; Lee 
et al., 2010), suggesting the potentials of anti-oxidants in the prevention of the disease (Kim et al., 
2015b; Lee et al., 2010). On the other hand, VD is caused by neuronal loss as a consequence of the 
lack of oxygen and nutrients due to vascular dysfunctions. Importantly, cardiovascular problems 
(including high blood pressure, high cholesterol, diabetes), and a history of depression are the 
common risk factors for both types of dementia (Alzheimer’s society, 2014a and 2014b), which 
indicates the significance of addressing those health issues to prevent the development of AD and VD. 
Of note, the hippocampus plays significant roles in memory formation and its dysfunctions are 
implicated in the aetiology of dementia (Lazarov and Hollands, 2016; Raskin et al., 2015).
Currently, there is no cure for dementia, and the mainstream drug intervention approach is to 
temporarily alleviate the symptoms by targeting the metabolism of acetylcholine (ACh), an essential 
neurotransmitter involved in cognitive processes. Reduced ACh levels in AD brain is implicated in 
cognitive decline (Vladimir-Knežević et al., 2014), and ACh-mediated signalling, particularly via 
nicotinic acetylcholine receptors, is thought to be a promising target in the symptomatic treatment of 
dementia (Lombardo and Maskos, 2015; Rusted et al., 2000). Donepezil, rivastigmine and 
galantamine are such drugs approved by Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA), which are categorised as cholinesterase inhibitors (ChEIs). These drugs 
enhance the local availability of acetylcholine by inhibiting its degradation enzyme 
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). While AChE is known as the major 
acetylcholine degradation enzyme in the brain, BuChE progressively accumulates in AD brain, 
indicating the involvement of both enzymes in dementia pathology (Lane et al., 2006). ChEIs have a 
modest but significant effect on the cognition, mood, and behaviour of AD patients (Grutzendler and 
Morris, 2001). However, the side effects of those ChEIs include dizziness, diarrhoea, headache, 
agitation, insomnia, and muscle cramps, which reduce the QoL of both patients and caregivers 
considerably, thus safer and more effective interventions are desired. 
1.2. Traditional knowledge on sage, rosemary, and lemon balm
Sage (Salvia officinalis L.), rosemary (Rosmarinus officinalis L.), and lemon balm (Melissa officinalis 
L.) have traditionally been known for their actions on mood and cognition. According to Culpeper 
(1616-1654), sage ‘is of excellent use to help the memory, warming and quickening the senses’ 
(Culpeper, 1653). John Gerard (1545–1612) wrote ‘sage is singularly good for the head and brain, it 
quickeneth the senses and memory’ (Dweck, 2000). Rosemary was mentioned in Hamlet by William 
Shakespeare (1564-1616): ‘There’s rosemary, that’s for remembrance’ (Hamlet, act IV scene V) 
(Shakespeare, 2015). The historical use of rosemary as a memory enhancer dates back to ancient 
Greece. It was mentioned by Pedanius Dioscorides (1st century AD) (Begum et al., 2013; Pengelly et 
al., 2012), and according to Nicholas Culpeper, rosemary ‘helps a weak memory, and quickens the 
senses’ (Culpeper, 1653). Culpeper also mentioned the use of lemon balm as a mood enhancer: lemon 
balm ‘causes the mind and heart to become merry, and reviveth the heart’ (Culpeper, 1653). 
According to Avicenna (Ibn-Sīnā, 980-1037), lemon balm was recognised an exhilarant (Alijaniha et 
al., 2015), while Paracelsus (1493-1541) recommended it for ‘all complaints supposed to proceed 
from a disordered state of the nervous system’ (Scholey et al., 2014). Of note, all these herbs belong 
to the same botanical family lamiaceae.
1.3. Rosmarinic acid 
Rosmarinic acid (α-o-caffeoyl-3,4-dihydroxyphenyllactic acid) is a natural phenolic compound first 
isolated from R. officinalis by Scarpati and Oriente in 1958 (Petersen and Simmonds, 2003). It is 
found abundantly in the members of botanical family lamiaceae, particularly in the subfamily 
nepetoideae (Barros et al., 2013). Table 1 shows the levels of rosmarinic acid in lamiaceae plants 
(Benedec et al., 2015; Kivilompolo and Hyötyläinen, 2007; Shekarchi et al., 2012; Wang et al., 2004; 
Zgórka and Głowniak, 2001). Among those, sage (S. officinalis), rosemary (R. officinalis), and lemon 
balm (M. officinalis) consistently contain high levels of rosmarinic acid (Table 1). Besides a number 
of important biological activities, such as anti-inflammatory, and anti-oxidative properties (Kim et al., 
2015a), rosmarinic acid is a potent inhibitor of AChE and BuChE (Orhan et al., 2008; Vladimir-
Knežević et al., 2014). In addition, rosmarinic acid protects hippocampal neurons against injuries 
(Kantar Gok et al., 2016; Zhang et al., 2016),  and can possibly enhance hippocampal functions 
(Hwang et al., 2016).  Considering the involvement of the hippocampus in dementia development 
(Lazarov and Hollands, 2016; Raskin et al., 2015), rosmarinic acid may prevent or delay the progress 
of dementia through improving hippocampal functions. Furthermore, rosmarinic acid inhibits γ-
Aminobutyric acid (GABA) transaminase (Awad et al., 2009), suggesting additional therapeutic 
benefits for accompanying symptoms such as anxiety, insomnia, and aggressive behaviour, by 
increasing GABA levels (Jembrek and Vlainic, 2015). 
Importantly, the dose of supposed active constituents in most phytomedicines are very low 
and it is believed that synergetic interactions between various components of herbs are vital part of 
their therapeutic efficacy (Williamson, 2001). In fact, lamiaceae plants are rich in volatile constituents 
with potential therapeutic benefits (Table 2) (Ali et al., 2015; Bozin et al., 2007; de Sousa et al., 2004; 
Gachkar et al., 2007; Mimica-Dukic et al., 2004; Porres-Martínez et al., 2015). For example, sage and 
rosemary are rich in volatile compounds with AChE and BuChE inhibitory properties, such as α-
pinene and 1,8-cineole, (Dohi et al., 2009; Orhan et al., 2008; Perry et al., 2003; Savelev et al., 2004). 
Lemon balm contains high levels of geranial and neral, monoterpene aldehydes related to geraniol and 
nerol, and these aldehydes are known to be anti-inflammatory (Gbenou et al., 2013; Shen et al., 2015). 
These volatile constituents can directly enter the blood stream through nasal and lung mucosa and 
affect autonomic nervous system and behaviour via pharmacological actions, as well as subjective 
experience of the odours (Herz, 2009; Heuberger et al., 2001). Of note, sedative properties are known 
for the essential oils of lamiaceae herbs, including Lavandula angustifolia Mill. and M. officinalis, 
whereas R. officinalis and S. officinalis essential oils are classified as stimulatory, in aromatherapy 
(Perry and Perry, 2006). Due to impaired olfactory abilities in dementia patients, aroma alone may not 
be sufficiently effective (Snow et al., 2004), however those volatile components, in combination with 
non-volatile constituents such as rosmarinic acid, could exert an synergetic benefits (Williamson, 
2001) in enhancing cognition and mood.
To evaluate potential benefits in dementia intervention of lamiaceae herbs, namely Salvia spp. (S. 
officinalis and S. lavandulaefolia Vahl), R. officinalis, and M. officinalis, we addressed the effects of 
these herbs on cognition, mood and QoL, in both dementia and non-dementia populations. 
2. Methods
2.1. Search strategy 
Database searches were conducted separately for each of the three herbs. Publications from 1960 to 
July 2017 were sought using databases PubMed/Medline, Cochrane Library, and ScienceDirect. 
PubMed searches were conducted in article type ‘Clinical Trial’ using search terms ‘((Salvia 
officinalis) OR Salvia lavandulaefolia) OR sage’ for sage, ‘(Rosmarinus officinalis) OR rosemary’ for 
Rosemary, and ‘(Melissa officinalis) OR lemon balm’ for lemon balm. Trials in Cochrane Library 
were sought using search terms ‘Salvia officinalis’ and ‘Salvia lavandulaefolia’ for sage, ‘Rosmarinus 
officinalis’ for rosemary, and ‘Melissa officinalis’ for lemon balm. In ScienceDirect, searches were 
conducted in the fields of ‘Medicine and Dentistry’, ‘Nursing and Health Professions’, and 
‘Pharmacology, Toxicology and Pharmaceutical Science’, using search terms ‘dementia AND “Salvia 
officinalis” OR “Salvia lavandulaefolia” for sage, ‘dementia AND “Rosmarinus officinalis”’ for 
rosemary, and ‘dementia AND “Melissa officinalis”’ for lemon balm. All searches were conducted in 
July 2017. 
2.2. Selection of studies
After database searching, abstracts were reviewed by the first author to identify studies that addressed 
the effect of a single species on cognition mood, or QoL. The exclusion criteria at abstract review 
were: 
1. Herbal formulae or combination of more than one species
2. No clinical diagnostic tests
3. No primary data
Due to the scarcity of data, randomised controlled trials, open-labels, as well as quasi-experimental 
trials were included, and healthy or cognitively impaired populations.  Flow diagrams were generated 
following PRISMA format (Moher et al., 2009) (Figure 1 – 3). After screening, both authors reviewed 
the full articles and synthesised the retrieved information.
3. Results 
3.1. S. officinalis and S. lavandulaefolia. 
S. officinalis has traditionally been used in European herbal medicine, however due to its high thujone 
levels, S. lavandulaefolia has been suggested to be an safer alternative (Mantle et al., 2000). This 
review includes both of these species in this review, as it is important to carefully consider the 
interchangeability and potential differences in efficacies. Total 263 records were retrieved though 
database searching (192 from PubMed, 36 from Cochrane Library, 35 from ScienceDirect), among 
which 235 were without overlap. Records were screened and 227 were excluded based on title and 
abstract, and 8 studies were selected for reviewing (Figure 1). The target population of the selected 
studies were heterogeneous: six studies on healthy volunteers (175 subjects in total) and two studies 
on mild to moderate dementia patients (53 subjects). Table 3 summarises the selected studies that 
investigated the efficacy of S. officinalis and S. lavandulaefolia in enhancing cognition and mood. In 
healthy young volunteers, the single oral administration of S. officinalis essential oil (50µL) enhanced 
cognition, alertness, and calmness (Kennedy et al., 2011; Tildesley et al., 2003; Tildesley et al., 2005), 
and S. officinalis dried leaves reduced anxiety at 300mg, while 600mg led to an increase in calmness 
and alertness and improved task performance (Kennedy and Scholey, 2006). The aroma of S. 
officinalis oil improved quality of memory, and the aroma of S. lavandulaefolia or S. officinalis oil 
enhanced alertness (Moss et al., 2010). S. officinalis alcoholic extract was effective in enhancing 
memory performance and accuracy of attention in healthy older adults at 333mg, while lower 
(167mg) or higher (666 and 1332mg) doses were ineffective (Scholey et al., 2008). An open trial with 
AD patients found that, oral administration of S. lavandulaefolia essential oil for 6 weeks, increasing 
dose from 50µL per day to 150µL per day over the course, led to a reduction in neuropsychiatric 
disturbances and trends towards improved memory and attention, although the latter was not 
statistically significant (Perry et al., 2003). In a 4-month intervention with AD patients, S. officinalis 
alcoholic extract 60 drops (3-6 mL) per day resulted in a significant cognitive improvement 
(Akhondzadeh et al., 2003b). 
3.2. R. officinalis
Total 118 records were retrieved though database searching (62 from PubMed, 19 from Cochrane 
Library, 37 from ScienceDirect), among which 112 were without overlap. After screening based on 
title and abstract, 107 were excluded, and five studies were assessed and selected for reviewing 
(Figure 2). All five studies were conducted on non-dementia subjects (total 234). The effects on 
cognition and mood have been studied with healthy volunteers, students with test-taking stress, and 
volunteers with low energy levels (Table 4). Moss et al. (2003) found that ambient aroma of R. 
officinalis can enhance mood and improve cognitive functions without speed-accuracy trade-off 
(Moss et al., 2003), while an active constituent 1,8-cineole was absorbed into the blood circulation 
and its serum levels correlated with improved cognitive performance (Moss and Oliver, 2012). 
McCaffrey et al. (2009) studied the effect of the aroma using an inhaler, and found that it can reduce 
anxiety in test-taking nursing student (McCaffrey et al., 2009). In addition, they compared rosemary 
and lavender and observed that both aromas were relaxing however R. officinalis assisted in 
concentration and recalling information whereas Lavandula hybrida was too relaxing and made it 
difficult to concentrate (McCaffrey et al., 2009). Lindheimer et al. (2013) reported that 1.7g mixture 
of R. officinalis and R. eriocalyx Jord. & Fourr. dried leaves (rosmarinic acid 20mg/g) reduced mental 
fatigue and false alarm errors in young adults with low energy states (Lindheimer et al., 2013), while 
Pengelly et al. (2012) found dose specific effects of R. officinalis dried leaves in improving in 
alertness and speed of memory at 0.75g, whereas 6.0g led to significant cognitive impairment and 
reduced alertness (Pengelly et al., 2012). 
3.3. M. officinalis
Among 200 records retrieved though database searching (125 from PubMed, 31 from Cochrane 
Library, 44 from ScienceDirect), 177 were without overlap. After screening based on title and 
abstract, 167 records were excluded and 10 studies were assessed for eligibility. Two records were 
excluded due to the fact that those were conference abstracts with the same contents from the same 
authors as one of the other records (Figure 3). Target populations of these trials were heterogeneous: 5 
studies on non-dementia individuals (total 139 subjects) and 3 studies on dementia patients (total 146 
subjects). The study designs and outcomes of the selected records are summarised in Table 5. In 
healthy volunteers, the oral administration of M. officinalis methanolic extract enhanced calmness at 
300 and 600mg and increased the speed of mathematical processing at 300mg, however reduced 
alertness and working and secondary memory at 600mg (Kennedy et al., 2004; Kennedy et al., 2002). 
Dried leaves was effective in Improving working memory, accuracy, and calmness at 1.6g, however 
not effective at lower dosages (0.6 and 1.0g) (Kennedy et al., 2003). Scholey et al. (2014) found no 
significant cognitive or mood enhancing effect by aqueous extract of M. officinalis (0.3 and 0.6g) 
(Scholey et al., 2014), however, due to complex matrices used in the study (yoghurt and tea-like 
drink), it is difficult to interpret the outcome of this trial. On the other hand, a 14-day trial in patients 
with heart palpitation using aqueous extract of M. officinalis (500mg) showed that it effectively 
reduced anxiety and insomnia (Alijaniha et al., 2015). In AD patients, a 4-month intervention with M. 
officinalis alcoholic extract 60 drops (3-6 mL) per day resulted in a significant improvement in 
cognition (Akhondzadeh et al., 2003a). Aroma therapy (massage, using the essential oil) for 12 weeks 
was effective in improving QoL in AD patients, although it was no more effective than control 
(massage without the essential oil) in reducing agitation, while massage led to a baseline improvement 
in agitation (Burns et al., 2011). This finding suggests that, while massage alone can be effective via 
sensory stimulation and human interaction (Cohen-Mansfield, 2013), there may not be any additional 
effect of M. officinalis essential oil in 3 months. On the other hand, a 4-month intervention with M. 
officinalis aromatherapy significantly reduced agitation and improved QoL in severe dementia 
patients (Ballard et al., 2002), suggesting that  aromatherapy could improve both psychiatric 
symptoms and QoL when applied for 4 months, but only QoL when applied for 3 months. 
4. Discussion
4.1. S. officinalis and S. lavandulaefolia
Among over 700 salvia species, S. officinalis and S. lavandulaefolia are the most common species in 
Europe and thought to have similar therapeutic properties (Perry et al., 1996; Savelev et al., 2004). 
However Savelev et al. (2004) found that essential oil of S. officinalis contained high levels of thujone 
(6.2%), whereas the levels in S. lavandulaefolia were below the detection limit (Savelev et al., 2004) 
(Supplementary table 1). Thujone is a modulator of GABAA receptor and can act as a convulsant 
(Höld et al., 2000; Olsen, 2000). EMA states that thujone intake should be limited to maximum 5mg 
per day and for up to two weeks (EMA, 2009), and S. lavandulaefolia has been suggested to be a safer 
alternative elsewhere (Mantle et al., 2000). However, thujone contents in S. officinalis can vary 
considerably depending on the geographical origin. For example, it may be absent in S. officinalis 
from Bulgaria (Cvetkovikj et al., 2015), as low as 4.5% for Greece origin, or as high as 36.8% for 
Estonian sample (Raal et al., 2007). In addition, although thujone can be toxic at high doses, it may 
have benefits within the safety limit, such as anxiolytic and antipsychotic actions of α-thujone (Deiml 
et al., 2004) and normalising effects on cholesterol and triglyceride levels (Baddar et al., 2011). These 
findings suggest that thujone could be beneficial in supressing dementia symptoms, as well as in 
reducing the risk of dementia development via anti-diabetic actions. S. officinalis may be superior in 
these respects. In fact, while anti-diabetes and anti-hyperlipidaemic effects of S. officinalis alcoholic 
and aqueous extracts have been supported by clinical evidence (Kianbakht et al., 2011; Kianbakht and 
Dabaghian, 2013), it is unknown whether S. lavandulaefolia can be equally effective. Of note, Salvia 
spp. contain camphor, which can be neurotoxic at large doses (Santos and Cabot, 2015), and S. 
lavandulaefolia contains camphor at considerably higher levels than S. officinalis (Supplementary 
table 1).
On the whole, clinical evidence suggests that Salvia spp. could have positive effects on 
cognition and mood. However, as Miroddi et al. (2014) pointed out, these clinical studies used a 
variety of herbal preparations, application methods, dosages, and intervention periods (Miroddi et al., 
2014), thus it is difficult to draw a single conclusion from these trials. In addition, while both essential 
oil and alcoholic extract of S. officinalis seem to be effective, only essential oil of S. lavandulaefolia 
was used in the trials, and much less is known as to non-volatile constituents of S. lavandulaefolia 
compared to S. officinalis. It is unknown whether the efficacy of S. officinalis alcoholic extract in AD 
patients (Akhondzadeh et al., 2003b) can be replaced by S. lavandulaefolia. Considering the safety 
concern due to thujone toxicity (Mantle et al., 2000), interchangeability of the two species, S. 
officinalis and S. lavandulaefolia, must be further addressed.
The use of S. officinalis for cognitive enhancement is not indicated in the EMA’s herbal 
monograph. However, EMA suggests the use of S. officinalis for ailments such as dyspepsia and 
excessive sweating, where alcoholic extract 2-3mL three times daily (6-9mL per day) or aqueous 
extract (infusion) of herbal substance 1-2g are indicated (EMA, 2009). The finding that 4-month 
intervention with S. officinalis alcoholic extract 3-6mL daily was well tolerated (Akhondzadeh et al., 
2003b) suggests that a moderate dosage of S. officinalis can be continuously administered for at least 
4 months without an major adverse effect for this purpose. 
4.2. R. officinalis
R. officinalis is rich in phenolic compounds, including rosmarinic acid, and diterpenes, which are 
strong anti-oxidant and can be neuroprotective (Habtemariam, 2016). In addition, it contains 1,8-
cineole and α-pinene in the essential oil, which are also antioxidants (Habtemariam, 2016) and potent 
AChEIs (Dohi et al., 2009; Perry et al., 2003). The presence of these compounds supports the 
traditional use of R. officinalis as a cognitive enhancer. In fact, the oral administration of R. officinalis 
extract improved spatial memory and enhanced the levels of antioxidants in the hippocampus in 
middle-aged rats (Rasoolijazi et al., 2015), improved cognitive impairment in scopolamine-induced 
rat dementia model (Ozarowski et al., 2013), and induced anxiolytic and anti-depressant-like effect in 
mice (Ferlemi et al., 2015). Clinical evidence suggests that both the oral administration herbal 
preparations (Lindheimer et al., 2013; Pengelly et al., 2012) and the aroma of essential oil (Moss et 
al., 2003; Moss and Oliver, 2012) can improve cognition, and the inhalation of essential oil can 
reduce anxiety (McCaffrey et al., 2009). Posology according to EMA herbal monograph indicates 
daily dose of 2-6g R. officinalis as herbal tea preparation (single dose 1-2g, 2-3 times daily), or liquid 
extract (1:1 in 45% ethanol) 2-4mL daily, for dyspepsia and mild gastrointestinal spasmodic disorders 
(EMA, 2010), suggesting that moderate doses below 2g of R. officinalis at a time, which is sufficed by 
the dosages used in the studies (Lindheimer et al., 2013; Pengelly et al., 2012), is safe and sufficient to 
exert some pharmacological effects. 
To summarise, the data indicate that single oral administration of R. officinalis leaves at a 
moderate dose, as well as essential oil aroma, can have positive effects on cognition and mood, while 
excess dosages have negative impacts, healthy individuals. However, further research must be 
conducted to address the therapeutic potential in the long-term, including effective dosages, duration, 
and safety in dementia patients. In addition, as shown by del Baño et al. (2003), rosmarinic acid 
content in R. officinalis leaves can vary considerably, ranging from 0.25 to 2.5 % dry weight, 
depending on harvest time (del Baño et al., 2003) and possibly on the climates and geographic 
regions, suggesting the necessity of standardisation according to the efficacy.  
4.3. M. officinalis
Rosmarinic acid is the most abundant phenolic compound in M. officinalis (Barros et al., 2013). By 
AChE inhibitory activity guided fractionation of M. officinalis alcoholic extract, rosmarinic acid was 
suggested to the major active constituent (Dastmalchi et al., 2009). In addition, M. officinalis 
methanol extract has GABA transaminase inhibitory effect, and the active principles are found to be 
rosmarinic acid, triterpenoids ursolic acid and oleanolic acid (Awad et al., 2009). Preclinical studies 
found that M. officinalis extract reduces serum corticosterone levels, decreases hippocampal GABA 
transaminase levels, and increases hippocampal neurogenesis (Yoo et al., 2011). Furthermore, it has 
anxiolytic-like effects under moderate stress conditions and does not alter activity levels (Ibarra et al., 
2010), indicating that M. officinalis can be effective in cognitive enhancement and protective against 
stress-related neuropathologies. In fact, clinical data suggest that M. officinalis can be beneficial in 
dementia intervention. While the single administration, in healthy individuals, of M. officinalis 
aqueous extract (0.3 and 0.6g) did not immediately improve cognition and mood (Scholey et al., 
2014), the alcoholic extract (0.3 and 0.6g) and dried leaves (1.6g) of M. officinalis exerted immediate 
cognition- and mood-enhancing effects (Kennedy et al., 2004; Kennedy et al., 2002; Kennedy et al., 
2003). The aqueous extract of M. officinalis (1g daily for 2 weeks) was effective in reducing anxiety 
and insomnia in heart palpitation patients (Alijaniha et al., 2015), while alcoholic extract (3-6mL 
daily) improved cognition in 4 months (Akhondzadeh et al., 2003a) and M. officinalis essential oil as 
aroma therapy improved QoL in 3 weeks (Ballard et al., 2002; Burns et al., 2011) and reduced 
agitation in 4 weeks in AD patients (Ballard et al., 2002). In addition, EMA herbal monograph 
indicates the use of M. officinalis for ‘relief of mild symptoms of mental stress and to aid sleep’, and 
suggests M. officinalis 1.5-4.5g as infusion or ethanolic extract, 1-3 times daily (EMA, 2013).  
4.4. Rosmarinic acid or herbal preparations
Although rosmarinic acid is an important common active constituent of S. officinalis, R. officinalis, 
and M. officinalis, it is questionable whether the efficacy of herbal preparations can be fully replaced 
by rosmarinic acid as a single compound. As discussed above, therapeutic actions of an herbal remedy 
involve multiple compounds, and those complex mechanisms could be beneficial in both enhancing 
the efficacies and reducing the potential side effects. In addition, unique constituents of each species, 
as well as the preparation methods and administration routes, can result in diverse therapeutic 
properties. For example, the profiles of volatile constituents are considerably different between those 
species (Table 5), and R. officinalis, and M. officinalis are used differently in aromatherapy: M. 
officinalis for insomnia and R. officinalis for memory loss (Ali et al., 2015). 
4.5. Issues and unanswered questions
Most studies were conducted on healthy individuals, addressing acute effects after a single 
intervention. However, as there are differences in the brain physiology between healthy and demented 
individuals, and what is needed in dementia care is to recover cognitive ability and reduce aberrant 
behaviours, as opposed to performance enhancement, it is questionable whether the observations in 
healthy subjects can be transferable to cognition and mood improvements in dementia patients. In 
addition, different methodologies employed in those studies (Supplementary table 2) may make a 
collective interpretation difficult. While most studies on healthy individuals were conducted using 
direct measures such as Cognitive Drug Research (CDR) computerised assessment battery and Bond–
Lader Visual Analogue Scales, cognition and behavioural issues in dementia patients were mainly 
assessed indirectly via interviews (Cognitive subset of the Alzheimer’s disease assessment scale), 
ratings by proxies or caregivers (Cohen-Mansfield Agitation Inventory, Neuropsychiatric Inventory), 
or observational ratings (Dementia Care Mapping, Pittsburgh Agitation Scale). In addition, the data 
discussed here are restricted to pre-defined parameters selected by the researchers, which are 
established under experimental settings, and we do not have access to parameters not included in the 
study or factors that are not yet defined in clinical trial settings. Nevertheless, evidence supports the 
effectiveness of Salvia spp. and M. officinalis in enhancing cognition and mood in dementia patients 
(Akhondzadeh et al., 2003a, b; Ballard et al., 2002; Burns et al., 2011; Perry et al., 2003). Although 
QoL assessment, as a measure of welfare (Bognar, 2005), is theoretically and methodologically 
complex and controversial (Ready and Ott, 2003), the findings that M. officinalis aromatherapy 
improved dementia patients’ QoL (Ballard et al., 2002; Burns et al., 2011) could have an important 
implication in achieving the ultimate goal of dementia intervention. 
Furthermore, as discussed above, the levels of active constituents in herbal materials can be 
considerably affected by environmental factors, thus standardisation is a critical issue to obtain 
reliable and reproducible therapeutic effects.  
4.6. Limitations of this review
Evidence is limited and there are some obstacles before reaching a final conclusion. Firstly, most 
studies are performed on healthy volunteers, and there is no data on dementia patients for R. 
officinalis. Secondly, herbal preparations and application methods used in those trials are diverse. 
More research will be needed on dementia patients using standardised herbal preparations at 
compound levels, such as rosmarinic acid and the volatile constituents. Finally, as dementia is a 
complex issue, cognitive performance alone may not be the good index of therapeutic effectiveness. 
We must consider a variety of beneficial outcomes, such as mood and QoL, to improve the wellbeing 
of dementia patients. A multifaceted study approach is desired.  
4.7. Perspectives
Lamiaceae herbs in general are easy to grow compared to those species that take years before 
harvesting, and no sustainability concern has been reported, at least for the three species studied in 
this report. Furthermore, there are other lamiaceae members potentially useful in dementia 
intervention. For example, Salvia miltiorrhiza Bunge (Chinese sage) is clinically used for treating 
cerebro- and cardio-vascular disorders and can be protective against diabetes-induced cognitive 
impairment (Cai et al., 2014; Hamidpour et al., 2014; Hügel and Jackson, 2014). It is also notable that 
Prunella vulgaris L. (self-heal) and Mentha spicata L. (spearmint) contain significantly high levels of 
rosmarinic acid (Table 1). Further investigation would be warranted for these species. Finally, while 
clinical trials can provide robust evidence to support the efficacy of a phytotherapy in a controlled 
setting, the effectiveness in a realistic environment may not solely be derived from the 
pharmacological actions of the chemical constituents, but could involve the subjective experiences 
based on personal and cultural background. This might be particularly the case when addressing mood 
and QoL, and the nature of traditional herbal medicine as a person-centred therapeutic approach 
(Roberti di Sarsina et al., 2012) is likely to play an important role in optimising the effectiveness of 
dementia intervention.
5. Conclusions
Herbal remedies have traditionally been used to improve cognition and mood, and ginkgo, bacopa, 
ginseng, sage, and rosemary are among the most frequently recommended. In this study, we have 
addressed the effectiveness of three lamiaceae members, namely sage, rosemary, and lemon balm. 
These herbs contain potentially effective constituents at high levels, and clinical evidence supports 
their effectiveness in improving cognition, mood, and QoL. However, for obvious ethical issues, there 
are few clinical studies with dementia patients, therefore it is yet to be elucidated what administration 
methods lead to optimal outcomes and how long it may be administered safely. In addition, the 
standardisation of herbal products at compound levels, as well as the specification of the safe and 
effective Salvia species, would be necessary before we reach a final conclusion. 
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Figure Legends
Figure 1. PRISMA flow diagram of the bibliographic review of S. officinalis and S. lavandulaefolia. 
Records screened (n = 235). Records assessed for eligibility and included in qualitative synthesis (n = 
8). 
Figure 2. PRISMA flow diagram of the bibliographic review of R. officinalis. Records screened (n = 
112). Records assessed for eligibility and included in qualitative synthesis (n = 5). 
Figure 3. PRISMA flow diagram of the bibliographic review of M. officinalis. Records screened (n = 
177). Records assessed for eligibility (n = 10) and included in qualitative synthesis (n = 8). 
Figure 4. Volatile constituents of the three Lamiaceae members. Common and unique essential oil 
constituents (Table 2) are graphically presented.
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Table 1: Rosmarinic acid contents in Lamiaceae species
Rosmarinic acid (mg/g)
Zgórka & 
Głowniak 
2001 #
Wang et al. 
2004 *
Kivilompol
o & 
Hyötyläinen 
2007 #
Shekarchi et 
al. 2012 §
Benedec et al. 
2015 **
Lavandula angustifolia 
Mill.
0.4 2.0 1.7 ± 0.2
Melissa officinalis L. 9.9 27.4 36.5 ± 0.8 7.84 ± 0.07
Mentha x piperita L. 0.9
Mentha spicata L. 7.1 – 14.3 5.62 58.5 ± 1.4
Ocimum basilicum L. 11.8 3.08
Origanum majorana L. 4.3
Origanum vulgare L. 5.98 25.0 ± 0.1 12.4 ± 0.08
Prunella vulgaris L. 21.7
Rosmarinus officinalis L. 6.5 10.0 – 11.0 9.16 7.2 ± 0.1 1.33 ± 0.01
Salvia officinalis L. 5.2 8.5 – 14.1 9.96 39.3 ± 0.9 2.12 ± 0.02
Satureja hortensis L. 12.2
Thymus vulgaris L. 5.5 4.5 – 8.7 9.96 23.5 ± 0.5
# 
 Methanol extract
* Ethanol:water (30:70) extract
§ 
 Water:methanol:2-propanol (80:10:10) extract
** Ethanol:water (70:30) extract
Table 2: Major constituents (%) in essential oils 
S. officinalis S. 
lavandulaefolia
R. officinalis M. officinalis
Bozin
2007
Ali 2015 Porres-Martinez 2013 Bozin
2007
Gachkar 
2007
Nimica-
Dukic 
2004
de Sousa 
2004
borneol 5.4 1.5 0.3 0.1 6.2 3.7
camphene 0.7 1.0 5.2 7.1 3.9 3.3 0.2
camphor 18.9 6.4 14.4 23.9 21.6 5.0
1,8-cineole 4.2 4.4 31.9 13.5 2.1 7.5
citronellal 13.7
geranial 23.4 47.3
limonene 1.0 21.7 2.2
linalool 1.1 14.9 0.8
menthol/isoment
hol
2.9 2.9
neral 16.5 39.3
α-pinene 1.5 1.9 9.0 11.7 13.5 14.9 0.3
piperitone 23.7
α-thujone 19.9 25.8 0.2
β-thujone 3.8 5.7
0.1 0.1
0.2 0.8
viridiflorol 17.5 20.4
Table 3: Clinical trials – S. officinalis and S. lavandulaefolia 
1st Author & 
Year
Target population 
& Intervention
Design & outcome 
measures
Results Summary
Kennedy, 2011 Population:
Healthy volunteers 
N=36 (26 women and 
10 men, aged 
23.8±4.38)
Intervention:
1. Treatment: capsules 
containing 
S.lavandulaefolia 
essential oil 50µL in 
olive oil
2. Control: Placebo 
capsules with olive oil 
only
Design: Single dose, 
double-blind, placebo-
controlled, balanced 
crossover
Outcome measures:
Pre-dose and 1 and 4h 
post-dose
1. Computerised Mental 
Performance 
Assessment System 
(COMPASS) (cognition 
and mood)
2. Cognitive Demand 
Battery: Serial 3s 
(speed/accuracy) and 
mental fatigue
3. Bond-Lader mood 
scales and State-trait 
anxiety inventory 
(STAI) subscale (mood/ 
well-being)
1. Improved 
performance of 
secondary memory 
and attention 
(pronounced at 1h)
2. Reduced mental 
fatigue and 
increased alertness 
(pronounced at 4h)
Herbal preparation, 
dosage and 
administration 
method:
S.lavandulaefolia 
essential oil, 50µL, 
acute oral
Overall outcomes:
Improved 
performance, 
attention, alertness; 
Reduced fatigue
Moss, 2010 Population:
Healthy volunteers 
N=45 (37 women 
aged 21.3±3.6, 8 men 
aged 22.4±3.0) for 
S.officinalis group; 
N=45 (36 women 
aged 21.3±4.9, 9 men 
aged 23.1±3.8) for 
S.lavandulaefolia 
group
Intervention:
1. Treatment: 
Aroma of S.officinalis 
or S.lavandulaefolia 
essential oils for 5 
min (5 drops in 5mL 
water, diffused in the 
testing cubicle) 
2. Control: No aroma
Acute olfactory* 
administration 
Design:
Single dose, single-
blind, one factor, 
independent group
Outcome measures:
1. A tailored Cognitive 
Drug Research 
computerised 
assessment battery 
(Assessed factors: 
quality of memory, 
speed of attention, 
accuracy of attention, 
speed of memory)
2. Bond-Lader mood 
scales (mod)
1. S.officinalis 
improved quality of 
memory**.
2. Both S.officinalis 
and 
S.lavandulaefolia 
enhanced alertness 
(subjective).
Herbal preparation, 
dosage and 
administration 
method:
S.officinalis or 
S.lavandulaefolia 
essential oils, acute, 
aroma
Overall outcomes:
Improved quality of 
memory by 
S.officinalis.
Enhanced alertness by 
S.officinalis and 
S.lavandulaefolia
Scholey, 2008 Population: Healthy 
older volunteers
N=20 (9 women and 
11 men, Aged 65-90)
Intervention:
Treatment: 
Standardised 70% 
ethanolic extract of 
S.officinalis dried 
leaf, lyophilised and 
powdered (167, 333, 
666, and 1332mg 
extract).
Acute oral 
administration
Design: Single dose, 
placebo-controlled, 
double-blind, balanced 
crossover
Outcome measures:
Cognitive Drug 
Research computerised 
assessment battery 
(Assessed factors: 
working memory, speed 
of memory, accuracy of 
attention, and speed of 
attention)
1. Significant 
enhancement of 
secondary memory 
performance* and 
improvements in 
accuracy of 
attention following 
333mg-dose**. 
2. No significant 
effect on working 
memory.
Herbal preparation, 
effective dosage and 
administration 
method:
70% ethanolic extract 
of S. officinalis dried 
leaf, 333mg, acute 
oral
Overall outcomes:
Enhanced memory 
performance and 
improved accuracy of 
attention only at 
333mg (not at 167, 
666, and 1332mg)
Kennedy, 2006 Population:
Healthy volunteers
N=30 (17 men and 13 
women, Aged 
24.4±4.4,)
Intervention:
1. Treatment: Opaque 
capsules containing 
dried leaf of 
S.officinalis 300 or 
600mg
2. Control: Inert 
placebo with the same 
appearance
Acute oral 
administration
Design: Single dose, 
placebo-controlled, 
double-blind, balanced 
crossover
Outcome measures: 1. 
Mood assessment at 
pre-dose and at 1 and 4h 
post-dose using Bond-
Lader mood scales and 
State Trait Anxiety 
Inventory (STAI) after 
stress*.
2. Task performance 
was assessed by DISS.
1. Improved mood: 
reduced anxiety by 
300mg **; 
increased alertness, 
calmness, and 
contentedness by 
600mg.
2. Improved task 
performance: higher 
Stroop Colour-word 
score by 600mg. 
(No difference in 
math, highest 
number tap, and 
memory search.)
Herbal preparation, 
dosage and 
administration 
method:
S. officinalis dried 
leaves, 300 and 
600mg, acute oral
Overall outcomes:
Reduced anxiety at 
300mg, increased 
alertness and 
calmness at 600mg, 
improved task 
performance at 
600mg
Tildesley, 2005 Population:
Healthy volunteers
N=24 (16 women and 
8 men, aged 18-37)
Intervention:
1. Treatment: 
Capsules of 25 or 
50µL of 
S.lavandulaefolia 
essential oil in 
sunflower oil
2. Control: Placebo 
capsules with 
sunflower oil only
Acute oral 
administration
Design: Single dose, 
placebo-controlled, 
double-blind, balanced 
crossover
Outcome measures:
1. Tailored version of 
Cognitive Drug 
Research computerised 
assessment battery 
(cognition)
2. Bond-Lader visual 
analogue scales (mood)
3. Numeracy (Serial 
Sevens test)
Pre-dose and post-dose 
(at 1, 2.5, 4, or 6h) 
measurement
1. ‘Speed of 
memory’ 
improvement by 25 
and 50µL.
2. ‘Secondary 
memory’ 
improvement by 
25µL. 
3. Mood 
enhancement: 
alertness, calmness, 
and contentedness 
by 50µL; calmness 
by 25µL
Herbal preparation, 
dosage and 
administration 
method:
S.lavandulaefolia 
essential oil, 25 and 
50µL, acute oral
Overall outcomes:
Speed of memory 
improvement at 25 
and 50µL, secondary 
memory improvement 
at 25µL,
enhanced alertness 
and contentedness at 
50µL, enhanced 
calmness at 25 and 
50µL
Tildesley, 2003 Population:
Healthy volunteers
Trial 1: N=20 (18 
women and 2 men, 
aged 18-31)
Trial 2: N=24 (16 
women and 8 men, 
aged 18-37)
Intervention:
1. Treatment: 
Capsules containing 
S.lavandulaefolia 
standardised essential 
oil (25, 50, 100, 
150µL) and sunflower 
oil 
2. Control: Placebo 
capsules containing 
sunflower oil alone 
Acute oral 
administration
Design: Single dose, 
placebo-controlled, 
double-blind, balanced 
crossover
Outcome measures: 
Tailored version of 
Cognitive Drug 
Research computerized 
assessment battery - 
Simple word recall 
(cognition)
Pre-dose and post-dose 
(at 1, 2.5, 4, or 6h) 
measurement
50µL dose 
improved 
immediate word 
recall when 
administered 1 or 
2.5h before test.
No effect at 25, 100, 
and 150µL.
Herbal preparation, 
dosage and 
administration 
method:
S.lavandulaefolia 
essential oil, 50µL, 
acute oral
Overall outcomes:
Improved cognition 
only at 50 µL (not at 
25, 100, and 150µL)
Perry, 2003 Population: 
Mild to moderate 
Alzheimer’s disease
N=11 (10 women and 
a man, aged 76-95)
Design: An open-label 
pilot study
Outcome measures: 
Cognitive Drug 
Research computerised 
1. Trends for 
improved memory 
and attention.
2. Statistically 
significant reduction 
Herbal preparation, 
dosage and duration:
S.lavandulaefolia 
essential oil, 50µL, 
increased dosage 1-3 
Intervention:
1. Treatment: 
Capsules containing 
50µL 
S.lavandulaefolia 
essential oil plus 
50µL sunflower oil.
Week 1 – one capsule 
at 8 am
Week 2 –at 8 am and 
7 pm, one capsule 
each
Week 3-6 – at 8 am, 7 
pm, 12:30 pm, one 
capsule each 
2. Control: None
assessment (cognition) 
and Neuropsychiatric 
Inventory (NPI) 
(psychopathology, 
including delusions, 
hallucinations, 
agitation, depression, 
anxiety, and appetite)
in neuropsychiatric 
disturbances.
times a day, oral, 6 
weeks
Overall outcomes:
Trends for improved 
memory and attention.
Reduction in 
neuropsychiatric 
disturbances
Akhondzadeh, 
2003
Population:
Mild to moderate 
Alzheimer’s disease 
(ADAS-cog ≥ 12; 
CDR ≤ 2)
N=42 (18 women and 
24 men, aged 65 – 80 
years)
Intervention:
1. Treatment: 
S.officinalis 1:1 
extract (dried leaves 
in 45% EtOH), 60 
drops per day, for 4 
months.
2. Control: placebo* 
60 drops per day
Design: Placebo-
controlled, parallel 
group
Outcome measures:
Change in Alzheimer’s 
Disease Assessment 
Scale (ADAS-cog) and 
Clinical Dementia 
Rating-Sum of the 
Boxes (CDR-SB) over 
the trial.
ADAS-cog: 
Significant 
improvement over 
the course between 
4-16 weeks. 
CDR-SB: 
Significant 
improvement over 
the course between 
8-16 weeks. 
Herbal preparation, 
dosage and duration:
S. officinalis 1:1 
extract (dried leaves 
in 45% EtOH), 60 
drops (= 3-6mL) per 
day, oral, 4 months
Overall outcomes:
Significant 
improvement in 
cognition
ADAS-cog, cognitive subscale of the Alzheimer’s disease assessment scale
CDR, clinical dementia rating
CDR-SB, clinical dementia rating–sum of the boxes
Table 4: Clinical trials – R. officinalis
1st Author & 
Year
Target population & 
Intervention
Design & outcome 
measures
Results Summary
Lindheimer, 
2013
Population:
Young adult with lack 
of energy (Mood 
States-Brief Form 
POMS-BF)
N=26 (rosemary) 
N=24 (placebo) 
(73% women, mixed 
ethnicity, aged 
20.8±3.4)
Intervention: 
1. Treatment: 
Capsules containing 
1.7g powdered 
mixture of 
R.officinalis and 
R.eriocalyx 
(rosmarinic acid 
content 20mg/g) 
2. Control: Placebo 
capsules containing 
3.1g rice flour
Acute oral 
administration
Design: Single dose, 
randomised, placebo 
controlled, double 
blind*, crossover
Outcome measures: 
1. Cognition measured 
by Bakan Vigilance 
Task 
2. Motivation and mood 
(subjective)
Pre-dose and post-dose 
at 60 and 90min
Small, transient 
reductions in false 
alarm errors and 
mental fatigue
Herbal preparation, 
dosage and 
administration 
method:
1.7g mixture of 
R.officinalis and 
R.eriocalyx, 
containing 
rosmarinic acid 
20mg/g, acute oral
Overall outcomes:
Transient reductions 
in false alarm errors 
and mental fatigue
Pengelly, 2012 Population: 
Healthy older adult, 
aged 65-90,
recruited via local 
media and networking
N=28 (20 women and 
8 men)
Intervention: 
1. Treatment: 
Powdered dried 
R.officinalis (0.75, 1.5, 
3.0, or 6.0g) in tomato 
juice
2. Control: Placebo – 
tomato juice without 
R.officinalis
Acute oral 
administration
Design: Randomised, 
placebo-controlled, 
double blind, repeated-
measures crossover
Outcome measures: 
1. Cognitive Drug
Research test battery 
(cognition)
2. Bond-Lader visual 
analogue scales (mood)
1. Dose specific 
improvement in 
‘speed of memory’ at 
0.75g dose, while 
6.0g had a negative 
impact. 
2. Improved alertness 
(subjective) at 0.75g.
2. Negative impact on 
‘continuity of 
attention’, and 
‘working memory’ at 
some doses.
Herbal preparation, 
dosage and 
administration 
method:
Powdered dried 
R.officinalis 
(0.75g) in tomato 
juice, acute oral
Overall outcomes:
Dose specific 
improvement in 
‘speed of memory’ 
and subjective 
‘alertness’ at 0.75g, 
while other dosages 
had some negative 
impacts.
Moss, 2012 Population: 
Healthy volunteers
N=20 (12 women aged 
23.2 ± 3.2 and 8 men 
aged 22.6 ± 2.9)
Intervention:
Treatment: 
Aroma of R.officinalis 
essential oil (4 drops 
on a diffuser pad in the 
testing cubicle, 
starting from 5 min 
prior to testing)
Design: Randomised, 
blind, parallel
Outcome measures: 
1. Computerised battery 
- serial trees, serial 
sevens, rapid visual 
information processing 
(RVIP) (cognition)
2. Bond-Lader Visual 
Analogue Scales 
(mood)
3. Blood test for 1,8-
cineole absorption
1. A positive 
relationship between 
serum 1,8-cineole 
levels and correct 
answers on serial 
threes task.
2. Negative 
relationship between 
serum 1,8-cineole and 
the reaction time on 
serial threes and serial 
sevens task. 
3. Negative 
relationship between 
serum 1,8-cineole and 
the reaction time on 
RVIP.
Herbal preparation, 
dosage and 
administration 
method:
R.officinalis 
essential oil, aroma, 
acute
Overall outcomes:
Positive correlations 
between serum 1,8-
cineole levels and 
cognitive 
performances.
4. Negative 
relationship between 
serum 1,8-cineole and 
contentedness.
McCaffrey, 
2009
Population: 
Test-taking graduate 
nursing students
N=40
Intervention:
1. Treatment: Essential 
oil inhaler of R. 
officinalis or 
Lavandula hybrida, 
prior to and during the 
test
2. No treatment for 
baseline
Design: Quasi-
experimental, crossover
Outcome measures: 
1. Anxiety measured by 
Test anxiety inventory 
(TAS) scores (pre- and 
post-test)
2. Blood pressure and 
radial pulse
3. Stress-reduction 
properties assessed by 
post-test discussion
1. Significant 
reduction in post-test 
anxiety by both 
R.officinalis and 
L.hybrida, however R. 
officinalis was 
superior to L. hybrida
2. No effect on blood 
pressure
3. Significant 
reduction in pulse by 
both R. officinalis and 
L. hybrid.
Herbal preparation, 
dosage and 
administration 
method:
R.officinalis 
essential oil, aroma 
(inhaler), acute
Overall outcomes:
Reduction in 
anxiety. 
Relaxing, and 
assisting in 
concentration and 
information recall.
Moss, 2003 Population:
Healthy volunteers
•Rosemary grope: 
N=48 (28 women aged 
25.3±6.9, 20 men aged 
23.8±7.8); •Lavender 
group: N=48 (27 
women aged 23.8±6.3, 
21 men aged 24.7±6.7)
Intervention:
1. Treatment: Aroma 
of R.officinalis 
essential oil 4 drops on 
a diffuser pad in the 
testing cubicle, 
starting from 5 min 
prior to testing
2. Control: Water 4 
drops instead of 
essential oil
Design: Randomised, 
blind, parallel
Outcome measures: 
Tailored version of the 
Cognitive Drug
Research computerised 
assessment system 
(cognition)
2. Bond-Lader visual 
analogue scales (mood)
1. Enhanced 
performance for 
overall quality of 
memory and 
secondary memory, 
but reduced speed of 
memory, in the 
treatment group
2. Improved alertness 
and contentedness in 
the treatment group.
Herbal preparation, 
dosage and 
administration 
method:
R.officinalis 
essential oil, aroma, 
acute
Overall outcomes:
Enhancement of 
performance for 
overall quality of 
memory and 
improved alertness 
and contentedness.
Table 5: Clinical trials – M. officinalis
1st Author & 
Year
Target population & 
Intervention
Design & outcome 
measures
Results Summary
Alijaniha, 2015 Population:
Volunteer adult 
outpatients with heart 
palpitation
•Treatment group: 
N=28 (17 women aged 
42.4±10.7)
•Control group: N=27 
(18 women aged 
41.1±12.3)
Intervention:
1. Treatment: Capsules 
containing 500mg 
lyophilised aqueous 
extract of M.officinalis 
leaves, twice a day 
(morning and night)
2. Control: Placebo 
capsules with similar 
appearance
Oral administration for 
14 days
Design: randomised, 
double-blind, placebo-
controlled
Outcome measures: 
1. Heart palpitation 
(subjective), evaluated 
by patient’s diaries and 
a self-report 
questionnaire.
2. Psychiatric symptoms 
(subjective) 
(somatisation, anxiety 
and insomnia, social 
dysfunction and 
depression) evaluated 
by General Health 
Questionnaire-28 
(GHQ-28)
M.officinalis 
treatment reduced 
frequency of 
palpitation, and 
reduced anxiety and 
insomnia.
Herbal preparation, 
dosage, 
administration 
method and 
duration:
500mg lyophilised 
aqueous extract of 
M.officinalis leaves, 
twice a day 
(morning and 
night), oral, for 14 
days 
Overall outcomes:
Reduced anxiety 
and insomnia
Scholey, 2014 Population:
Healthy volunteers
Study 1 (Tea-like 
drink): N=25 (17 
women and 8 men, 
aged 18-39)
Study 2 (Yoghurt):
N=21 (8 women and 
13 men, aged 21-30)
Intervention:
1. Treatment: Dried 
aqueous extract of 
M.officinalis 
(rosmarinic acid > 6%) 
in tea-like drink or 
yogurt
2. Control:
Tea or yoghurt without 
M.officinalis extract 
with artificial 
sweetener
Design: Double-blind*, 
placebo-controlled, 
crossover
Outcome measures: 
1. Cognitive Drug 
Research computerised 
assessment battery 
(cognition and mood)
2. State-Trait Anxiety 
inventory (mood)
3. Bond-Lader Visual 
Analogue Scales 
(mood)
4. Profile of Mood 
States (POMS) (mood)
5. Spielberger State 
Anxiety Questionnaire 
(mood)
6. Cortisol levels
1. Significant 
reduction in salivary 
cortisol levels at 1h 
after M.officinalis in 
drink.
2. No significant 
improvement in mood 
and cognition.
Herbal preparation, 
dosage, 
administration 
method:
Dried aqueous 
extract of M. 
officinalis leaves, 
0.3 or 0.6g in tea-
like drink or 
yoghurt, oral, single 
dose
Overall outcomes:
No significant 
improvement in 
mood and cognition
Burns, 2011 Population:
Older people (> 60 
years) with Alzheimer 
disease and agitation.
•M.officinalis group: 
N=32 (21 women and 
11 men)
•Donepezil: N=31 (20 
women and 11 men)
•Placebo group: N=31 
(15 women and 16 
men)
Intervention:
1. Treatment: 
M. officinalis 
aromatherapy (10% 
Design: Randomised, 
double-blind, parallel-
group, placebo 
controlled
Outcome measures: 
1. Agitation assessed by 
Pittsburgh Agitation 
Scale (PAS, 
observational)
2. Behavioural and 
psychological 
symptoms assessed by 
Neuropsychiatric 
Inventory (NPI)
Not superior 
compared to placebo 
or donepezil in 
reducing agitation 
(PAS) and 
observational 
psychological 
symptoms (NPI), 
however effectively 
improved Quality of 
Life (Blau QOL 
scale).
Herbal preparation, 
administration 
method and 
duration:
M.officinalis 
essential oil, 
aromatherapy 
(massage), 12 
weeks
Overall outcomes:
Effective in 
improving QoL, 
however not 
superior to placebo 
in reducing 
agitation or 
essential oil applied to 
the skin 1-2min)
and placebo 
medication
2. Donepezil 
medication and 
placebo aromatherapy 
(sunflower oil)
3. Control: 
Placebo medication 
and aromatherapy 
(sunflower oil)
4-week interventions 
and 12-week follow-
ups.
3. Quality of life 
measured by the Blau 
QoL scale
observational 
psychological 
symptoms
Kennedy, 2004 Population:
Healthy volunteers
N=18 (8 women and 
10 men, aged 29.11 ± 
6.81)
Intervention:
1. Treatment: capsules 
containing M. 
officinalis 
methanol:water 
(30:70) extract, dried, 
300mg or 600mg
2. Control: placebo
Acute oral 
administration
Design: Single dose, 
randomised, placebo 
controlled, double-
blind, balanced 
crossover
Outcome measures: 
Defined Intensity 
Stressor Simulation 
(DISS) computerised 
battery (cognitive and 
psychomotor tasks) – 
medium 
difficulty/intensity 
level, for cognition;
Bond-Lader Visual 
Analogue Mood Scales 
for mood.
1. Reduction in DISS-
induced negative 
mood and
increased calmness 
and reduced alertness 
(self-rated) by 600mg.
2. Increase in the 
speed of mathematical 
processing by 300mg.
Herbal preparation, 
administration 
method and 
duration:
M. officinalis 
methanol:water 
(30:70) dried 
extract, 300mg or 
600mg, oral, single 
dose 
Overall outcomes:
Reduction in 
negative mood and 
alertness and 
increased calmness 
at 600mg.
Increased speed of 
mathematical 
processing by 
300mg.
Akhondzadeh, 
2003
Population:
Patients with mild to 
moderate Alzheimer’s 
disease
N=42 (18 women and 
24 men, aged 65-80)
Intervention:
1. Treatment: 
M.officinalis leaf 
extract (1:1 in 45% 
alcohol, standardised 
> 0.5mg/mL citral) 60 
drops/day
2. Control: placebo 60 
drops/day
Oral, for 4 months
Design: Randomised, 
placebo controlled, 
double-blind, parallel 
group
Outcome measures: 
Change in Alzheimer’s 
Disease Assessment 
Scale (ADAS-cog) and 
Clinical Dementia 
Rating-Sum of the 
Boxes (CDR-SB) over 
the trial.
Improvement in 
treatment group, 
while decline in 
placebo group, in both 
ADAS-cog and CDR-
SB scores over the 4 
months.
Herbal preparation, 
administration 
method and 
duration:
M.officinalis leaf 
extract (45% 
alcohol), 60 
drops/day, oral for 4 
months
Overall outcomes:
Improved cognition
Kennedy, 2003 Population:
Healthy volunteers
N=20 (14 women and 
6 men, aged 18-23)
Intervention:
1. Treatment: capsules 
containing 0, 600, 
1000, or 1600 mg of 
M.officinalis leaf
2. Control: placebo 
capsules
Design: randomised, 
placebo-controlled, 
double-blind, balanced 
crossover
Outcome measures: 
1. Cognitive Drug 
Research computerised 
assessment battery 
(cognition)
2. Bond-Lader visual 
analogue scales (mood)
1. Improved working 
memory and 
accuracy, and 
calmness at 1600mg.
2. Slower 
performance and 
decreased accuracy at 
600 and 1000mg. 
Herbal preparation, 
administration 
method and 
duration:
1.6g of M.officinalis 
leaves, oral, single 
dose
Overall outcomes:
Improved working 
memory and 
Acute oral 
administration
accuracy, and 
calmness.
Kennedy, 2002 Population:
Healthy volunteers
N=20 (15 women and 
5 men, aged 18-22)
Intervention:
1. Treatment: Capsules 
containing 
M.officinalis leaf 
methanol:water 
(30:70) extract, 300, 
600, or 900mg
2. Control: Placebo
Acute oral 
administration
Design: Single dose, 
randomised, placebo-
controlled, double-
blind, balanced-
crossover
Outcome measures: 
1. Cognitive Drug 
Research computerised 
assessment battery and 
serial subtraction 
(cognition)
2. Bond–Lader Visual
Analogue Scales 
(mood).
Measured at pre-dose, 
post-dose (1h, 2.5h, 4h, 
and 6h)
1. Improved accuracy 
of attention, but 
reduced working & 
secondary memory at 
600mg. 
2. Elevated calmness 
by 300mg and 
reduced alertness by 
600mg.
Herbal preparation, 
administration 
method and 
duration:
M.officinalis leaf 
methanol:water 
(30:70) extract, 300 
or 600mg, oral, 
single dose
Overall outcomes:
Improved accuracy 
of attention, but 
reduced working & 
secondary memory 
and alertness at 
600mg. 
Elevated calmness 
at 300mg
Ballard, 2002 Population:
Severe dementia 
patients
N=72 (36 for each 
group - female 20 for 
treatment and female 
23 for control, aged 
77.2±7.6 for treatment 
and 79.6±8.5 for 
control)
Intervention:
1. Treatment: 
M.officinalis essential 
oil (aromatherapy)
2. Control: Sunflower 
oil
Topical application to 
the face and both arms 
twice a day, total 
200mg of oil 
(combined with base 
lotion), for 4 weeks
Design: Randomised, 
placebo-controlled, 
parallel
Outcome measures: 1. 
Cohen-Mansfield 
Agitation Inventory 
(CMAI)
2. Neuropsychiatric 
Inventory (NPI)
3. QoL measured by 
Dementia Care 
Mapping
M.officinalis was 
Significantly more 
effective than control 
in reducing agitation 
and improving QoL
Herbal preparation, 
administration 
method and 
duration:
M.officinalis 
essential oil, 
aromatherapy 
(topical 
administration to 
the face and arms), 
4 weeks
Overall outcomes:
Reduced agitation 
and improved QoL
 
Supplementary table 1: Comparison of essential oil contents between S. officinalis and S. 
lavandulaefolia 
Potential 
toxicity and 
pharmacolo
gical actions
S. officinalis
(% in essential oil)**
S. lavandulaefolia 
(% in essential oil)**
Savel
ev et 
al., 
2004
Mirjal
ili et 
al., 
2006
Darwis
h et al. 
2013
Hamidp
our, et 
al. 
2014
Savel
ev et 
al., 
2003
Perry 
et al., 
2001
Savel
ev et 
al., 
2004
thujone 
(α & β)
Toxic at 
high doses, 
GABAA and 
5-HT3 
inhibition
6.2 13.9 2 - 6 2.1-3.3 - 0.28 -
camphor Toxic at 
high doses, 
TRPV3 
activation
11.0 7.1 5 - 10 8.0-
10.0
24.7 27 42.5
1,8-
cineole
AChE 
inhibition
5.4 16.8 37 - 60 55.0-
62.0
26.8 17 17.4
α-pinene 
(camphene*
)
AChE 
inhibition
(1.2) 2.7 
(3.4)
3 - 10 3.7-4.5 
(2.6-
5.0)
6.6 5 -
* Camphene can be a by-product of α-pinene during the processing
** Data adopted from Savelev et al. (2004)
Supplementary table 2: Assessment methods used in the trials
Test 
(References) 
Applications Factors assessed Other notes 
Bond-Lader Visual 
Analogue Scales
(Bond and Lader, 
1974; Hasson and 
Arnetz, 2005)
1. To assess subjective 
feelings.
2. Used for sedative drug 
effects etc.
Mental sedation, physical 
sedation, and calmness
1. Subjective measures of 
mood
2. 16 scales
3. Easier to use (but might 
be less specific/precise) 
compared to Likert scale
Clinical Dementia 
Rating scale - Sum of 
the Boxes (CDR-SB)
(O'Bryant et al., 2008)
Diagnosis of dementia.
(Not able to assess 
cognitive decline in the 
normal population)
Global cognitive function 1. Involves structured 
interviews to determine the 
presence of dementia.
2. Lacks sensitivity and 
precision.
Cognitive Drug 
Research (CDR) 
computerised 
assessment battery
(Thomas Gualtieri, 
2004)
1. To assess cognitive 
impairment related to a 
variety of disorders 
including dementia, drugs, 
and environmental toxins. 
2. To differentiate different 
conditions causing dementia 
(AD, Huntington’s disease, 
Parkinson’s disease, mild 
cognitive impairment, and 
stroke) 
Attention, executive 
function and working 
memory, episodic 
secondary memory, motor 
skill
1. Automated.
2. Yes or No. 
3. Records the accuracy and 
reaction time.
4. Additional tests can be 
added to the standard battery
Cognitive subset of 
the Alzheimer’s 
disease assessment 
scale (ADAS-cog)
(Mohs et al., 1997; 
Rosen et al., 1984)
Diagnosis of dementia. 
(Not able to assess 
cognitive decline in the 
normal population)
Global cognitive function 1. Involves structured 
interviews to determine the 
presence of dementia.
2. Lacks the sensitivity and 
precision.
3. Administration by paper 
and pencil
Cohen-Mansfield 
Agitation Inventory 
(CMAI)
(Cohen-Mansfield et al., 
1989)
To assess the frequency of 
manifestations of agitated 
behaviours in elderly 
persons.
Abusive or aggressive 
behaviours, normal 
behaviours with 
inappropriate frequency, 
inappropriate behaviours 
according to social norm
1. Caregivers’ rating 
questionnaire.
2. Rating 1-7 for 29 
descriptors. 
Computerised 
Mental 
Performance 
Assessment System 
(COMPASS)
(Brain, performance and 
nutrition research 
centre)
1. To assess Mood and 
cognition.
2. Sensitive in nutraceutical 
intervention.
Mood and cognitive 
factors such as working 
memory, attention, and 
executive function
1. Automated.
2. Can do parallel stimuli 
(multi-tasking)
3. Flexible. 
Dementia Care 
Mapping
(Brooker, 2005)
To assess the well-being of 
dementia
Behaviours with high or 
low potential for well-
being, personal 
detractions, positive 
events
1. Observational
2. Involves one or two 
trained mappers
3. Well- or ill-being (6-point 
scale from extreme ill-being 
to extreme well-being)
Neuropsychiatric 
Inventory (NPI)
(Cummings et al., 1994; 
Forester and Oxman, 
2003)
1. To assess the presence of 
psychopathology in patients 
with brain disorders
2. Widely used to measure 
the outcome of 
interventions, particularly 
anti-dementia agents
Delusions, hallucinations, 
agitation/aggression, 
depression/dysphoria, 
anxiety, elation/euphoria, 
apathy/indifference, 
disinhibition, 
irritability/lability, 
aberrant motor behaviour
1. Caregivers’ rating 
questionnaire
2. Rating the frequency on a 
4-point scale, the severity on 
a 3-point scale, and the 
distress on a 5-point scale
Pittsburgh Agitation 
Scale (PAS)
(Rosen et al., 1994) 
To assess agitation in 
patients with dementia.
Observational measures 
of behaviours: aberrant 
vocalisation, motor 
agitation, aggressiveness, 
resisting care
1. Observational rating 
(direct observation over 1 to 
8 hours by clinical staff)
2. Measured on an intensity 
scale of 0-4
Test Anxiety Scale 
(TAS)
(Sarason, 1984)
Anxiety in reaction to test-
taking
Subjective anxiety True or False judgment for 
about 40 descriptors
Bakan Vigilance 
Task
(Bakan, 1959)
A state of readiness to 
detect and respond to 
environmental stimuli.
Auditory vigilance. Primary and secondary 
auditory signals. (Bakan, 
1959)
